Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
• Applying scientifi c knowledge to the identifi cation and<br />
pre-clinical validation of novel anti-cancer drugs:<br />
• generation of new markers for tumours, valuable tools<br />
for prognosis;<br />
• development of peptides and monoclonal antibodies:<br />
by studying diff erent DRs and their respective ligands,<br />
the Consortium will validate targets in mouse models<br />
through the development of recombinant proteins and<br />
monoclonal antibodies;<br />
• development of anti-cancer agents: the data collected<br />
through this project will provide the basis for the development<br />
of small molecules as anti-cancer agents.<br />
Potential applications<br />
HERMIONE will enable better understanding of how dysfunctions<br />
in dependence receptors signalling can lead to<br />
tumour formation and/or progression. The knowledge generated<br />
will be applied to the generation of targeted drugs,<br />
providing safer and more eff ective treatments for patients.<br />
The work performed within this project will include the<br />
development of new biomarkers that will provide means for<br />
both diagnosis and prognosis. The amount of fundamental<br />
knowledge generated within the project will allow better<br />
comprehension of the events linking dependence receptors<br />
to tumour progression and provide targets to modulate<br />
apoptosis of tumour cells. This will provide valuable data to<br />
identify Dependence Receptors that could be involved in<br />
other types of cancer.<br />
Screen for apoptosis genes by highly specialised custom-made robots.<br />
210<br />
Coordinator<br />
Patrick Mehlen<br />
Centre Léon Bérard<br />
Lyon, France<br />
mehlen@lyon.fnclcc.fr<br />
Partners<br />
Jurg Tschopp<br />
Université de Lausanne<br />
Lausanne, Switzerland<br />
Giovanni Romeo<br />
Alma Mater Studiorum<br />
Universita di Bologna<br />
Bologna, Italy<br />
Project number<br />
LSHC-CT-2006-037530<br />
EC contribution<br />
€ 2 364 909<br />
Duration<br />
36 months<br />
Starting date<br />
01/11/2006<br />
Instrument<br />
STREP<br />
Project website<br />
http://hermionetypo.<br />
prodige.com/<br />
Olivier Donze<br />
Apotech Corporation<br />
Epalinges, Switzerland<br />
Stefan Grimm<br />
Imperial College of Science,<br />
Technology and Medicine<br />
London, United Kingdom<br />
John Hickman<br />
Institut de Recherche Servier<br />
Suresnes, France<br />
Raffaella Catena<br />
Alma Consulting Group<br />
Lyon, France<br />
CANCER RESEARCH PROJECTS FUNDED UNDER THE SIXTH FRAMEWORK PROGRAMME
Change language